BankofVol Grift
Publisher of Bank of Volatility, AI/ML Trading Bots
Kura Oncology's 15% one-day jump is pure ticker confusion, making it the cleanest fade on the tape if puts are liquid. Trump's Q1 disclosure showed $1-5M in "Kura," meaning Kura Sushi USA, but retail bought Kura Oncology, an unrelated clinical-stage cancer biotech now at a $917M market cap. The intended buy may even have been Fujikura, a Japanese fiber-optic supplier. Options activity is extreme for a thinly traded stock, with a 0.007 put/call ratio and no fundamental anchor. x.comÂ
Kura Sushi could follow semiconductors higher now that President Trump is reportedly long the stock, since his semiconductor buying preceded their explosion. Per @aleabitoreddit, Trump took a large stake, close to 0.8% of the roughly $600m company if he bought $5M. x.comÂ
Kura Sushi is one of the better restaurant names, and the dip looks like a good buy, in line with Trump's apparent view. The Cupertino location near Apple's headquarters always had an hour-long line, and new locations have opened around Berkeley and elsewhere. x.com x.comÂ
Heavy CEO buying in these healthcare stocks, with charts showing bottoming, suggests many could be multi-baggers in the medium term. Kura Oncology's CEO bought $2.35M at 52-week highs as its menin inhibitor took most new patient starts; Prenetics' CEO bought three times in a week; PROCEPT's new CEO and Boston Scientific's CEO, with $9M, bought after big declines; Mesa Labs' CEO made his first-ever buy; ProQR's CEO more than tripled his stake; Tiziana's CEO bought 1.4% of its market cap. x.com … Show more
Kura Sushi is leveraging up in the restaurant sector and will be bankrupt in six months. Per Bloomberg, the conveyor-belt sushi chain targets 20% annual US store growth, betting it can build market share before a wave of competitors arrives. x.comÂ
